Filing Flows › QuidelOrtho (QDEL) › Q2 2026 › vs Q2 2025
QuidelOrtho (QDEL) Q2 2026 vs Q2 2025 (year over year)
QuidelOrtho's revenue rose $17.0M (+3%) from $614M in Q2 2025 to $631M in Q2 2026.
QuidelOrtho, Q2 2026: revenue $631M (+3% year over year), operating margin -3.5%, net loss $92.9M, operating cash flow −$111M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $631M | $614M | $17.0M | +3% |
| Net loss | $92.9M | $255M | −$162M | -64% |
| Costs & expenses | $724M | $869M | −$146M | -17% |
| Operating costs | $653M | $795M | −$142M | -18% |
| Interest & other, net | $59.4M | $48.9M | $10.5M | +21% |
| Income tax | $11.7M | $25.8M | −$14.1M | -55% |
| Cost of revenue | $358M | $339M | $19.0M | +6% |
| Research & development | $48.7M | $45.7M | $3.0M | +7% |
| SG&A | $190M | $178M | $11.7M | +7% |
| Other operating costs | $56.3M | $232M | −$176M | -76% |
| Operating cash sources | $239M | $170M | $69.4M | +41% |
| Depreciation & amortization | $117M | $110M | $6.4M | +6% |
| Share-based compensation | $12.0M | $12.8M | −$800K | -6% |
| Cash used in operations | $111M | $46.8M | $63.8M | +136% |
| Net loss absorbed | $92.9M | $255M | −$162M | -64% |
| Working capital & other | $146M | −$85.5M | $232M | — |
Questions
How much did QuidelOrtho's revenue grow year over year in Q2 2026?
QuidelOrtho's revenue rose $17.0M (+3%) from $614M in Q2 2025 to $631M in Q2 2026.